Loading
A phase 1/2 trial of Sacituzumab tirumotecan, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) is a phase 1/2 interventional study registered as NCT06483334 by Merck Sharp & Dohme LLC, with 38 participants enrolled, started 2024-07-17 and due to reach its primary completion in 2028-03-31. Interventions recorded: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab and Supportive care measures.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/